Prior to joining eFFECTOR, Dr. Webster was Vice President of Oncology Research at AstraZeneca Pharmaceuticals, where he led the oncology discovery organization in Waltham, MA. In this role he served on the global oncology leadership team accountable for science strategy, leading the transformation to patient-based drug discovery. He oversaw the delivery of a project portfolio spanning discovery and early clinical development. During his tenure with AstraZeneca he was accountable for building a new drug discovery bioscience organization in the US, as well as spearheading the creation of novel partnerships with academia and biotech organizations. Prior to AstraZeneca, Dr. Webster served as a member of the oncology drug discovery leadership team at Bristol Myers Squibb where he led the cell cycle and apoptosis research areas and delivered multiple discovery research projects from inception through early clinical development. Dr. Webster holds a Ph.D. in Molecular Biophysics and Biochemistry from Yale University where he studied protein-RNA interactions and translational regulation. Dr. Webster graduated with honors from the State University of New York at Stony Brook with a B.S. in Biochemistry.